A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
The study will last about 284 weeks and may include 30 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participants must have a diagnosis of JIA-U or chronic anterior antinuclear antibody (ANA) positive uveitis without systemic features
Participants must have active anterior uveitis
Participants must have an inadequate response or intolerance to MTX
Participants must be on a stable dose of corticosteroid eye drops
Participants and their partners must be willing to use two forms of birth control
Participants must not have of any autoimmune inflammatory condition other than JIA
Participants must not have had eye surgery within the 3 months
Participants must not have an infection
Participants must not have hepatitis B or tuberculosis (TB)